Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2001
Volume 25
Issue 10

The author proposes a strategy for achieving a successful partnership with Big Pharma on the basis of forming a relationship with the company, deliberately managing the alliance, and clearly defining roles and responsibilities.

External Link - article-4522.pdf

Articles in this issue
Outsourcing Outlook
Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films
Hydrogels for the Controlled Release of Pharmaceutical Proteins
Near-Infrared Inspection Complements Other QC Systems
Safety and Manufacturing Standards
System Optimization for In Situ Fiber-Optic Dissolution Testing: Hydrodynamic Effects, System Performance, and Applications
Current Status of the Oral Delivery of Insulin
Laboratory Equipment Qualification
Filter Integrity Testing in Liquid Applications, Revisited, Part I
360&#176 Feedback &#45 Improving the Selection Process All the Way Around
Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AbbVie to Boost Immunology Pipeline with Acquisition of Nimble Therapeutics

Feliza Mirasol
December 18th 2024
Article

AbbVie's latest acquisition target is Nimble Therapeutics, which will give AbbVie a lead asset, an oral peptide for treating psoriasis.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

Feliza Mirasol
December 12th 2024
Article

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novartis Enters $2.9 Billion License Agreement with PTC Therapeutics for Huntington’s Disease Development Program

Feliza Mirasol
December 10th 2024
Article

Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.